Based on in vivo results, the exosome-delivered siRNA silencing RRM2 demonstrated noticeable melanoma growth regression, suggesting the RNA-targeted exosome delivery system with RRM2siRNA could attenuate tumor growth. Here, RRM2 is linked to neoplasm.